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ABSTRACT
Aquaculture has grown rapidly as the world’s wild-caught fisheries approach their
sustainable limits. Feed conversion in aquaculture is more efficient than in terrestrial
animals. Thus with a growing world population, seafood produced through aquaculture
can provide a high quality source of protein. Aquaculture systems rely on high stocking
densities and commercial feeds to increase production and profitability, which increase
animal stress and susceptibility to disease. Veterinary drugs are commonly used to
prevent and treat disease outbreaks. Several of these drugs are banned for use in
shrimp farming in the United States. These drugs can be toxic to humans, with side
effects that can be fatal. There is also an increased risk of developing antibiotic resistant
strains of human pathogens, including Bacillus and Vibrio species. The Food and Drug
Administration is responsible for the safety of all fish and fishery products entering the
United States, but funding for testing is limited. Examples of drugs with high
enforcement priority include chloramphenicol, nitrofurans, fluoroquinolones and
quinolones, malachite green, and steroid hormones. State testing has repeatedly
resulted in the detection of banned drugs. The objective of this study was to quantify
veterinary drug residues in commercially available frozen shrimp.
Imported, farm-raised shrimp samples were purchased from local supermarkets
and include shrimp from seven brands and six different countries. A preliminary
screening was done using rapid ELISA kits to test for chloramphenicol, malachite green,
nitrofurans, and fluoroquinolones. Samples tested positive for malachite green and
fluoroquinolones; all samples tested negative for chloramphenicol and nitrofurans.
ELISA results were confirmed using liquid chromatography with tandem mass
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spectrometry. Drug residues in shrimp samples were confirmed for chloramphenicol at
concentrations ranging from 0.30 to 0.49 ppb, and enrofloxacin from 1.22 to 5.95 ppb.
Results suggest that current testing by the FDA may not be adequately addressing
imported seafood safety. Concurrently analyzed wild-caught shrimp from the US tested
negative for all veterinary drugs considered.	
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CHAPTER 1. LITERATURE REVIEW
1.1 Introduction
Aquaculture has grown rapidly as the world’s fisheries have reached their
sustainable limits. Aquaculture systems rely on high stocking densities and commercial
feeds to increase production and profitability, which increases animal stress and
susceptibility to disease. Veterinary drugs, including those that are known to cause
adverse human health effects, are commonly used to prevent and treat disease
outbreaks, making routine testing essential.
Several veterinary drugs are illegal for use in food-producing animals in the United
States because of their toxicity to humans, their linkage to fatal diseases, and antibiotic
resistance in human pathogens including Bacillus and Vibrio species. The Food and
Drug Administration is responsible for the safety of all fish and fishery products entering
the United States, but funding for testing is limited. State testing has repeatedly resulted
in the detection of banned veterinary drugs. Current testing and enforcement may be
insufficient. Contaminated product is still entering the country because exporting
countries often don’t have sufficient resources for alternative means of combating
disease.
Previous studies have focused on the use of veterinary drugs in aquaculture,
including the history of their use, their impacts on the environment and human health,
the toxicity of historically used antimicrobials, and alternatives to unsafe veterinary
drugs. Methods have been developed for the rapid screening of animal and food
samples using enzyme-linked immunosorbent assays (ELISA), and several methods
have been developed for the detection of veterinary drug residues. The best and most
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sensitive method is high-pressure liquid chromatography (HPLC) with tandem mass
spectrometry (MS/MS). The instrument significantly reduces background signal and
allows measurement at very low levels.
The purpose of this study was to screen for and confirm the presence of illegal
veterinary drug residues in shrimp. Commercially available frozen shrimp samples were
tested for chloramphenicol, fluoroquinolones, malachite green, and nitrofurans, which
are drugs that have high enforcement priority in the United States due to their adverse
health affects. The methods used to confirm the presence of residues were procedures
preferred by FDA laboratories for the detection of drug and chemical residues in food.
In this thesis, we describe a series of experiments to screen for the four
aforementioned veterinary drugs using ELISA and confirm positive results using LCMS/MS. A review of related literature, description of methods used, results, and a
discussion of the results follow.
1.2 Shrimp Aquaculture
Aquaculture is the farming of aquatic organisms, including both plants and
animals, with the implication of some form of intervention in the rearing process, such
as regular stocking, feeding, or protection from predators. The primary purpose of
aquaculture is for food production, but it is also used for recreation, stock restoration,
and biofuel production. Information about the early history of aquaculture is unclear;
however, there is evidence of commercial fish farming in Egypt as early as 2500 BC and
detailed records of aquaculture in China from 1100 BC 1. Early aquaculture production
was characterized by low stocking densities and utilized minimal inputs in the form of
land, water, feed, fertilizers, and energy.
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Interest in the culture of shrimp was prompted by an increased market demand
and the inability of capture fisheries to meet that demand 2. The shrimp farming industry
experienced rapid growth and diversification in the 1980s 1with market expansion
occurring in economically advanced countries 2. The export market and opportunity to
earn foreign exchange attracted support from individual governments and international
assistance agencies and investment by private industry 2. Developing countries were
provided financial assistance from the World Bank system, beginning as capital
investment and expanding to include extension, research, training, and technology
development, with the primary recipients being China and India 1.
The rapid growth in population during the 20th century contributed to an
increased demand for seafood. As capture fisheries reached their maximum sustainable
limits at 90 million metric tons per year, the aquaculture industry has grown at an
accelerated rate to become a major contributor to the world fish supply 3. Over the last
five decades, the world fish food supply has grown dramatically due to steady growth in
fish production and improved distribution channels. Between 1980 and 2010, world food
fish production by aquaculture grew by nearly 12 times. In 2011, annual global
aquaculture production accounted for 41% of total world fisheries production by weight4.
In 2012, more than 91% of the total supply of edible fishery products in the United
States was from imports, and shrimp imports, valued at $4.5 billion, accounted for 27
percent of the value of total edible imports 5.
Protein-energy malnutrition is a leading contributor to the global burden of
disease 6. Almost 20% of the world population’s consumption of animal protein intake is
from finfish and shellfish 4. Seafood production from aquaculture provides an essential
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source of protein for the growing human population3, thus making aquaculture an
important animal food-producing sector and important cash crop in both developed and
developing countries7. In 2012, the major exporters of shrimp to the US (by volume)
were Thailand, Ecuador, Indonesia, India, Viet Nam, and China 5. The contribution of
aquaculture to the world’s production of seafood is expected to increase. Aquaculture is
a viable option in developing nations because it offers opportunities to alleviate poverty
by increasing employment and community development and reduces the
overexploitation of natural resources 8. Seafood is a more efficient protein source
compared to other major commercial species; the feed conversion ratio (FCR) for fish is
lower, meaning that fish requires less feed mass input to produce the same amount of
body mass output. Fish do not expend energy to maintain body temperature, they use
less energy to maintain their position, and lose less energy in protein catabolism and
excretion of nitrogen.
In shrimp culture there are differences among various species with respect to
environmental requirements, feeding, behavior, and compatibility with other species 2.
Considerations to take into account include water salinity (10-40 ppt), temperature
tolerance (18-33 °C), the character of soil in the culture facilities, feed quality, and
response to high-density culture 2. The compatibility of different penaeid species in
polyculture is highly dependent upon these factors, but rotational production of different
species can be done according to seasonal changes of salinity and temperature 2. The
most common species of aquacultured shrimp are the white leg (Penaeus vannamei)
and black tiger (Peneaus monodon) species. P. vannamei originate from the eastern
Pacific Ocean, from Sonora, Mexico to Peru, and are ideal for farming because of their
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ability to grow in very shallow water 9. These shrimp grow up to 230 mm in length and
have a maximum carapace length of 90 mm. P. vannamei is a highly euryhaline species
that can tolerate salinities ranging from 0-50 ppt and temperatures from 22-32 °C 2. P.
monodon are native to the western Indo-Pacific, from southeast Africa to Pakistan and
Japan 9. The maximum length of these shrimp is 336 mm and they weigh from 60 to
130 grams 9. P. monodon is euryhaline and can withstand almost fresh-water
conditions, although 10-25 ppt is considered optimum, and their temperature tolerance
ranges from 12-37.5 °C 2.
Shrimp culture is mainly carried out using traditional pond systems. While
traditional systems utilized natural stocking through the intake of tidal water carrying
large numbers of shrimp larvae, hatchery units and nursery ponds are now used to grow
larvae to an advanced juvenile stage before transfer to production ponds. Although
earthen ponds are the predominate system in shrimp aquaculture, farms with semiintensive culture systems often have nurseries and rearing ponds with concrete dikes 2.
Recirculating aquaculture tank production systems are generally used for intensive
shrimp and prawn culture, where water is continually exchanged and recycled to
maintain dissolved oxygen levels and remove metabolic waste products. Biological
filtration using nitrifying bacteria and solids removal are important components of
recirculating systems. Certain species can be produced using raceway systems, in
which water is exchanged multiple times daily 2.
1.3 Veterinary Drug use in Shrimp Aquaculture
Worldwide, aquaculture systems continue to increase in number and intensity in
response to the rising demand for aquaculture products. 3. The tremendous increase in
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aquaculture production has been accompanied by potentially detrimental health effects
in human and animals associated with the dissemination of considerable quantities of
veterinary drugs into the environment 10. As has occurred in other types of animal
husbandry, the expansion and intensification of commercial aquaculture has increased
stressors under which fish are being raised, resulted in the prevalence of pathogens in
both culture systems and the natural aquatic environment, and made imperative the use
of veterinary medicines to maintain healthy stocks, prevent and treat disease outbreaks,
and maximize yield 8,11. The intensification of culture methods is accomplished through
high stocking densities, the use of medicated feeds, and the heavy application of
pesticides. 3. The types of medication used to treat aquatic species include vaccines,
antibiotics, antiparasitics, antifungal agents, and immunostimulants 12. The use of these
products, with the intent to improve health management and biosecurity within
aquaculture, has made it possible to achieve great advances in aquaculture production
capacity 8.
In developing countries, the use of a veterinary drugs is prevalent in intensive
marine shrimp farming to achieve sustainable production. Important issues that effect
drug use in the aquaculture industry include the integrity of the environment, the safety
of target animals and humans who consume them, and the safety of persons who
administer the compounds. There are three primary ways in which antibiotics are used
in aquaculture: 1) therapeutically, to treat existing disease, 2) prophylactically, at
subtherapeutic concentrations, and 3) subtherapeutically, for production
enhancement13. Antibiotics are typically administered in the water, often as components
of fish feed, and are occasionally injected 13.
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1.4 Impact on the Environment and Human Health
Using large amounts of a variety of antibiotics, including non-biodegradable
antibiotics and those that are important for use in human medicine, ensures that they
remain in the aquatic environment and exert selective pressure for long periods of
time10. Veterinary drugs are deposited in the environment in the form of uneaten food
and fish waste. Thus, they can penetrate into the sediment, be carried by currents to be
dispersed over a wide area, and be ingested by wild fish and shellfish 10. Veterinary
drug use in aquaculture can result in a reduction in mortality during disease events and
an overall better survival rate 14; however, it is important to consider the potential
negative impacts, including environmental degradation, the development of
antimicrobial resistance among bacterial pathogens, and toxicological effects on nontarget organisms.
1.4.1 Environmental Impacts
The benefits of shrimp aquaculture are numerous, but adequate environmental
safeguards must be in place to prevent environmental degradation. The main
environmental effects of marine aquaculture are caused by the introduction of invasive
species that threaten biodiversity, organic pollution and eutrophication, chemical
pollution, and habitat modification 15. The presence of unconsumed fish feed and
metabolic waste increases the input of nitrogen, carbon, and phosphorous into the
aquaculture environment and results in eutrophication 10. Furthermore, aquaculture
environments and the fish and shellfish harvested from them can have elevated levels
of antibiotic residues, antibiotic-resistant bacteria, and organic pollutants compared to
their wild counterparts 3.
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The existence of large amounts of antibiotics in the water and sediment can
affect the flora and plankton in culture systems, causing shifts in the diversity of the
microbial communities and affecting the structure and activity of microbiota 16. Several
groups of veterinary drugs are known to be of environmental concern because of their
historical, measurable impacts on the environment 17. The heavy use of antibiotics
inhibits the microbiota at the base trophic level in the water and sediment from
performing important metabolic functions, promoting algal blooms and anoxic conditions
that could potentially lead to impacts on fish and human health 10.
1.4.2 Antimicrobial Resistance
Antibiotics are important for human therapy as well as disease management in
aquaculture, but their prudent and responsible use is essential because of their ability to
pollute the environment and challenge microbial populations. The widespread use of
antimicrobial agents in shrimp culture has led to accumulation of residues in the water
and sediment and the emergence of antimicrobial resistance in in environmental
bacteria 18. It has also resulted in an increase of antimicrobial resistance in shrimp
pathogens and the transfer of resistance determinants to terrestrial bacteria and human
pathogens 19,20. Antimicrobial resistance is a major public health concern and is widely
recognized as a priority issue for the aquaculture industry. Antibiotic residues and
resistant bacteria, including resistant strains of Vibrio and Bacillus species, have been
detected in Vietnamese shrimp ponds 19. The extent of antimicrobial resistance resulting
from antimicrobial use in aquaculture is yet to be determined 21.
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There are two types of hazards associated with antimicrobial resistance, as
identified by the 1996 Joint FAO/OIE/WHO Expert Consultation on Antimicrobial Use in
Aquaculture and Antimicrobial Resistance: the development of acquired resistance in
aquatic bacteria that can infect humans, and the development of acquired resistance in
bacteria in aquatic environments whereby such resistant bacteria can act as a reservoir
of resistant genes that can be further disseminated and ultimately end up in human
pathogens 22. The human health consequences of antimicrobial resistance in bacteria
include an increased frequency of treatment failures and an increased severity of
infection, which can lead to longer illness duration, increased frequency of bloodstream
infections, and higher mortality 22. High-risk populations include individuals working in
aquaculture facilities, populations living around aquaculture facilities, and consumers
who regularly eat aquaculture products 3. Although there are no documented cases of
human infections from antimicrobial resistant bacteria from aquaculture products 14,
there is a need for better information about the potential for human exposure to
contaminants and human health risks 3.
1.4.3 Residues of Food Safety Concern
In addition to posing environmental problems and creating antimicrobial
resistance, the use of veterinary drugs or their residues in commercialized shrimp
products can cause serious toxicity. Acute and chronic toxicities have been evaluated
and are well documented in literature 13. In most cases, the amount of drug residues
ingested by an individual who consumes contaminated animal tissues will be
considerably less than that consumed as a primary drug 23. The lack of documented
cases of direct toxicity from antibiotics and their metabolites in animal tissue indicates
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that the probability of occurrence is extremely low 24,25. There is exception in
chloramphenicol, a drug that causes dose-independent aplastic anemia 13.
The United States Food and Drug Administration’s Center for Veterinary
Medicine (CVM) is responsible for setting enforcement priorities for drug use in shellfish
for human consumption. Enforcement priorities are based on the safety status of the
compound, user safety, environmental safety, and the extent of data available for
enforcement priority determination. Known or suspected carcinogens and known
serious toxicological hazards are high priority compounds. Examples of drugs with high
enforcement priority include chloramphenicol, nitrofurans, fluoroquinolones and
quinolones, malachite green, and steroid hormones 26.
1.4.4 Chloramphenicol
Chloramphenicol

Figure 1.1: Chemical structure of chloramphenicol
Introduced in 1949, chloramphenicol was the first broad-spectrum antibiotic 27. It
was isolated from Streptomyces venezuelae in soil from Venezuela and was widely
used because of its high efficacy against a wide range of organisms, low cost, and ease
of synthesis and administration 28. In the early 1950s, serious toxicities related to
chloramphenicol administration were reported in adults and children, and its use began
to decline. Two types of chloramphenicol toxicity are potentially fatal: idiosyncratic
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aplastic anemia and dose-dependent gray baby syndrome. The most common toxicity is
reversible, dose-dependent bone marrow suppression which occurs due to inhibition of
mitochondrial membranous protein synthesis and results in immune system
impairment29. Grey baby syndrome is a potentially fatal disease that can occur in
children as well as adults and is characterized by abdominal distension, vomiting,
metabolic acidosis, progressive pallid cyanosis, irregular respiration, hypothermia,
hypotension, and vasomotor collapse 28. Using the recommended reduced dosage of
chloramphenicol for infants and neonates can prevent gray baby syndrome 27. The
development of aplastic anemia after oral administration of chloramphenicol occurs in
genetically predisposed individuals and is well-established, but must be taken into
perspective; while fatal aplastic anemia is estimated to occur in one of 24,500 – 40,800
cases 30, fatal anaphylaxis occurs in one of 67,000 patients treated with penicillin.
Chloramphenicol is widely used in veterinary medicine for both food and
companion animals because of its activity against the main veterinary pathogens. While
it has never been approved for use in food-producing animals in the United States, it is
used extensively in other countries to treat bacterial infections 28.
1.4.5 Fluoroquinolones
Ciprofloxacin

Enrofloxacin

Figure 1.2: Chemical structures of enrofloxacin and primary metabolite ciprofloxacin
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Fluoroquinolones are broad-spectrum antibiotics that are used to treat bacterial
diseases in aquaculture and have been associated with multiple, severe toxicities,
including hemolysis, renal failure, thrombocytopenia, and cardiac arrhythmia 31. The
most commonly observed adverse affects during therapy with fluoroquinolones are
reactions of the gastrointestinal tract and central nervous system. The development of
quinolone drugs began with the non-fluorinated drug nalidixic acid in the early 1960s
and continued in the 1980s with the first 6-fluorinated derivatives, which have enhanced
activity against Gram-negative bacteria31.
1.4.6 Malachite Green
Malachite
Green

Leucomalachite
Green
	
  

Figure 1.3: Chemical structures of malachite green and primary metabolite
leucomalachite green
Malachite Green is most commonly known for its use in the dye industry and as a
therapeutic agent for fish 32. It has been widely used all over the world in the fish
farming industry as a fungicide, ectoparasiticide, and disinfectant. However, it is highly
cytotoxic to mammalian cells, with the ability to induce cell transformation and lipid
peroxidation, thereby acting as a liver tumor enhancing agent 33. Human exposure to
malachite green occurs most notably through its use as an antifungal agent in
aquaculture systems. Malachite green is metabolized to leucomalachite green upon
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absorption into the tissue, thus the method of analysis must be capable of determining
both compounds to detect its presence in seafood products 32.
The discovery of toxic health effects of malachite green led to the prohibition of
its use in food production by the US FDA, but because it is effective, readily available,
and relatively inexpensive, it has been used in aquaculture since the early 1930s and is
considered the most effective antifungal agent by many in the fish industry 34. Therefore,
consumers of farmed fish and workers in the aquaculture industry are at risk for
exposure to malachite green 32. Malachite green is structurally similar to other
triphenylmethane dyes, such as gentian violet, which are known to be carcinogenic 35.
Studies indicate that malachite green causes reproductive abnormalities in rabbits and
fish 36 and enhances the formation of hepatic tumors in rats 8. Concern over exposure to
malachite green is attributable to studies suggesting it may cause adverse effects, but
there is inadequate evidence to evaluate carcinogenicity or determine the risk of
exposure to the dye 32.
1.4.7 Nitrofurans

Furaltadone

AMOZ

Figure 1.4: Chemical structures of furaltadone and primary metabolite 3-amino-5morpholinomethyl-2-oxazolidinone (AMOZ)
Nitrofurans are a group of synthetic, broad-spectrum antibiotics characterized by
the 5-nitrofuran ring in their structure and by their effectiveness against bacteria. The
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most widely used nitrofurans are furazolidone, furaltadone, nitrofurazone, and
nitrofurantoin. In the tissue, these compounds metabolize to 3-amino-2-oxazolidinone
(AOZ), 3-amino-5-methylmorpholino-2-oxazolidinone (AMOZ), semicarbazide (SEM),
and 1-aminohydantoin (AHD). Detection of nitrofurans is based on the determination of
the metabolites. Due to concerns about potential carcinogenicity of the drug residues
and their potential to cause harmful effects on human health, the FDA banned their use
in food-producing animals in 2002, but residues continue to be found in imported shrimp
because of their ready availability for veterinary therapy. Animal studies have resulted in
tumor production from dietary exposure to nitrofurans 37.
In the United States and Europe, any confirmed concentration of nitrofuran
residues in edible animal tissues is prohibited, although the European Commission has
established a maximum residue performance limit (MRPL) of 1µg/kg for nitrofuran
metabolites 37. Nitrofuran antibiotics are cheap and effective for the promotion of growth
and prevention of disease and are therefore still used in some countries. This
necessitates sampling and monitoring procedures in order to ensure consumer safety37.
Studies on the stability of nitrofuran metabolites have demonstrated that 67-100% of
residues remain after storage and cooking by a variety of methods 38.
1.5 Alternatives to Antibiotics in Aquaculture Disease Management
The need to minimize the use of antibiotics in aquaculture disease management
is widely recognized by the aquaculture industry and academia, and research has
focused on methods to reduce the impact of disease in aquaculture 39. The aquaculture
industry has experienced major losses caused by disease outbreaks, relying on nonselective chemotherapeutic agents or antimicrobials that not only target the pathogen,
	
  
	
  

14

	
  
but also affect normal flora. Alternatives to antimicrobial agents for the management of
disease in aquaculture systems include vaccination, immunostimulants, probiotics,
bioremediators, bacteriophage therapy, and holistic approaches 14.
Good aquaculture practices (or best aquaculture practices) are essential for the
reduction of stress and promotion of animal health. The establishment of these
procedures can substantially reduce issues associated with disease and the need for
chemotherapeutic intervention 40. Vaccination has proven successful for bacterial
disease prevention in salmonid aquaculture, but there are few vaccines available for
shrimp because of the poorly developed immune systems of invertebrates 39.
Immunostimulants have been used to modulate immune responses in finfish and
shellfish aquaculture and have the potential to improve resistance against a wide range
of pathogens 39. Probiotics such as Bacillus, Vibrio, and Pseudomonas spp. are widely
used in shrimp aquaculture in order to enhance the populations of beneficial
microorganisms, improve water and sediment quality, suppress pathogenic bacteria,
stimulate the immune system, and improve digestion 41. The use of bioremediators such
as nitrifying and photosynthetic bacteria to manage the environment are promising
alternatives for disease prevention and outbreak management 39. Bacteriophage
therapy is now being explored in the medical field for treatment of antibacterial-resistant
pathogens and has potential application in aquaculture. Bacteriophages only lyse target
bacteria, unlike antibiotics, and would not suppress the beneficial flora 39.
There are a number of alternative options available for health and disease
management in aquaculture to reduce reliance upon antimicrobial agents 39. Healthy
seed supply, probiotic use, optimum water quality maintenance, and lower stocking
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densities are suggested for the control of disease in shrimp farming 42. The use of
alternatives to antimicrobial agents in aquaculture is critical for the protection of human
and animal health and experience in other sectors of animal husbandry has
demonstrated that these changes can be made without detrimental financial effects 10.
1.6 Laws and Regulations for Veterinary Drug Use in Aquaculture
1.6.1 International Regulations
The issue of antimicrobial resistance among bacterial pathogens caused by the
use of antimicrobial drugs in aquaculture has been deliberated for a considerable length
of time, but improved laboratory methods for detecting drug residues around 2001 led to
heightened concern associated with the use of drugs in aquaculture and disruptions of
trade in aquaculture products 14. The World Trade Organization’s Agreement on the
Application of Sanitary and Phytosanitary Measures (SPS Agreement) sets the basic
rules for food safety and gives countries the right to set their own standards to protect
the health of their citizens, using whatever measures and inspection methods they
determine to be appropriate for their consumers. The regulations must be based on
available scientific evidence and should not be used to favor domestic industry 14.
At the international level, the Codex Alimentarius Commission (CAC) is
responsible for providing advice on risk management concerning veterinary drug
residues. The Joint FAO/WHO Expert Committee on Food Additives (JECFA) provides
independent scientific advice for risk assessment through the evaluation of available
data 14. The risk assessment process is used to establish acceptable daily intake (ADI)
and maximum residue limits (MRLs) to protect the health of consumers and ensure fair
trade of foods 7. Veterinary drugs with toxic or carcinogenic potential, such as
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chloramphenicol and nitrofurans, are not evaluated and, therefore, no ADI or MRL is
established. These drugs are banned for use in food-producing animals in most
countries 14. Regulatory authorities generally adopt a zero tolerance approach for
veterinary drugs without an established ADI/MRL, and the major veterinary drugs
involved are chloramphenicol, nitrofuran metabolites and malachite green 14.
1.6.2 United States Regulations
The United States of America is a member of the Codex Alimentarius
Commission. The United States Food and Drug Administration (FDA) has jurisdiction
over veterinary drugs and farmed shrimp in the United States. The legal marketing and
use of veterinary drugs in the US is determined by the Federal Food, Drug, and
Cosmetic Act (FFDCA) and its amendments 7. Approvals are for specific products and
include evaluation of human food safety, target animal safety and effectiveness,
environmental safety, and user safety 43. The agency works with individual states to
ensure the safety of seafood products, approve drugs and feed additives, monitor
manufacturing, distribution, and use of fish drugs, provide technical assistance and
training, and provide the necessary oversight required to ensure fish food products are
safe, wholesome, and properly labeled 53.
The US FDA’s Center for Veterinary Medicine (FDA-CVM) animal drugs and
animal feed and therefore has a critical role in protecting human and animal health in
the United States. The agency ensures the safety and effectiveness of animal drugs
and is responsible for the safety of treated seafood products in the US. The CVM
recognizes that antimicrobial resistance is an important public health issue and
addresses potential risks associated with the use of antimicrobials in animals through
	
  
	
  

17

	
  
the new animal drug approval process, post-approval monitoring, and surveillance 7. A
new animal drug is considered to be unsafe and in violation of the law if its use does not
conform to its FDA approved, conditionally approved, or indexed indications. The
agency may deny approval if the proposed use of a drug fails to meet FDA’s reasonable
certainty of no harm standard 7.
The FDA prohibits the extra-label use of certain drugs or classes of drugs in
food-producing animals that pose a risk to public health. The following drugs (both
animal and human formulations), families of drugs, and substances are prohibited for
extra-label uses in food-producing animals:
•

Chloramphenicol

•

Clenbuterol

•

Diethylstillbestrol

•

Ipronidazole

•

Other nitroimidazoles

•

Furazolidone, Nitrofurazone, other nitrofurans

•

Sulfonamide drugs in lactating dairy cattle

•

Fluoroquinolones

•

Glycopeptides7.

Typically, the FDA pulls samples randomly from various importers and tests them in
their own laboratories. If positives are found, an import alert is issued against the foreign
supplier and all products coming into the country from that supplier must have testing
done by a private laboratory until multiple shipments pass the specifications for
antibiotics.
	
  
	
  

18

	
  

CHAPTER 2. MATERIALS AND METHODS
2.1 Sample Procurement
Twenty-seven frozen samples of imported, farm-raised shrimp were obtained
from five retail grocery stores in Baton Rouge, Louisiana. Samples included shrimp from
Thailand, India, Indonesia, Vietnam, China, Ecuador, Vietnam-Thailand, and IndiaIndonesia. Fourteen frozen samples of domestic, wild-caught shrimp were obtained
from six retail grocery stores in Baton Rouge, LA. Frozen samples were transported to
the Department of Food Science at Louisiana State University Agricultural and
Mechanical College in Baton Rouge, LA and were stored at -80°C until further
processing.
2.2 ELISA Screening
ELISA test kits were purchased from Bioo Scientific Corporation (Austin, Texas)
to screen for four aquaculture drug residues: MaxSignal Chloramphenicol ELISA Test
Kit (1020-03A), MaxSignal Fluoroquinolone ELISA Test Kit (1024-01), MaxSignal
Malachite Green/Leucomalachite Green Test Kit (1019-06A), and MaxSignal
Furaltadone (AMOZ) ELISA Test Kit (1020-03A). The kit components were stored at
8°C, according to the manufacturer’s instructions. Frozen shrimp samples were
prepared and analyzed according to the protocols provided with the test kits. Shrimp
samples were homogenized using a food processor (Kitchen Aid Contour Silver 7 Cup –
Model #KFP0711CU). Optical densities of samples were measured using a Model 680
Microplate Reader (Bio-Rad Laboratories, Hercules, CA). Standard curves were
constructed by plotting the mean relative absorbance (%) obtained from each reference
standard against its concentration in ng/mL on a logarithmic curve. The mean relative
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absorbance values for each sample were used to determine the corresponding
concentration of the tested drug in ppb.
2.2.1 Chloramphenicol
Three grams of the homogenized sample was weighed into 15 mL centrifuge
tubes, mixed with 6 mL of ethyl acetate, then vortexed for 3 minutes at maximum speed.
The sample was centrifuged for 5 minutes at 4,000 x g at room temperature and 4 mL of
the ethyl acetate supernatant was transferred into a new 15 mL centrifuge tube. The
sample was dried at 60°C using a centrifugal solvent evaporator. The dried residue was
dissolved in 2 mL of n-hexane and 1 mL of Sample Extraction Buffer was added and
mixed by vortexing at maximum speed for 2 minutes. The sample was centrifuged for
10 minutes at 4,000 x g at room temperature and the upper hexane layer was
discarded. One hundred microliters of the lower aqueous layer was used per well for the
assay (dilution factor = 5).
One hundred microliters of each CAP standard and each sample was added in
duplicate into different wells. 50 µL of CAP-HRP conjugate was added and the plate
was incubated for 1 hour at room temperature in the dark. The plate was washed 3
times with 250 µL of Wash Solution. One hundred microliters of TMB substrate was
added and the plate was incubated for 20 minutes at room temperature. After
incubation, 100 µL of Stop Buffer was added to stop the enzyme reaction and the plate
was read immediately at 450 nm wavelength.
2.2.2 Fluoroquinolones
Fat was not removed from the sample, as per the manufacturer’s instruction. One
gram of the homogenized sample was weighed into 15 mL centrifuge. Four milliliters of
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70% methanol was added and vortexed for 10 minutes at maximum speed. The sample
was centrifuged for 5 minutes at 4,000 x g at room temperature and 0.5 mL of the
supernatant was transferred to a new 15 mL centrifuge tube. 0.5 mL of Sample
Extraction Buffer was added and mixed well. Fifty microliters was used for the assay
(dilution factor = 10).
Fifty microliters of each enrofloxacin standard and each sample was added in
duplicate into different wells. One hundred microliters of Antibody #1 was added and the
plate was incubated for 30 minutes at room temperature. The plate was washed 3 times
with 250 µL of Wash Solution. One hundred microliters of TMB substrate was added
and the plate was incubated for 15 minutes at room temperature. After incubation, 100
µL of Stop Buffer was added to stop the enzyme reaction and the plate was read
immediately following the addition of Stop Buffer on a microplate reader at 450 nm
wavelength.
2.2.3 Malachite Green
Two grams of the homogenized sample was weighed into 15 mL centrifuge
tubes. One milliliter of Sample Extraction Buffer A, 0.4 mL of Sample Extraction Buffer B
and 6.0 mL of acetonitrile were added and vortexed for 4 minutes at maximum speed.
The sample was centrifuged for 10 minutes at 4,000 x g and 2 mL of the upper organic
layer was transferred to a new 15 mL centrifuge tube containing 300 mg of MG Clean
Up Mix. The sample was vortexed for 1 minute at maximum speed and left at room
temperature for 10 minutes then centrifuged for 10 minutes at 4,000 x g. One milliliter of
the supernatant was transferred to a 2 mL microcentrifuge tube and dried. One hundred
microliters of Oxidant Solution was added to the dried sample and vortexed vigorously
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for 1 minute, centrifuged for 10 seconds, and left at room temperature for 15 minutes.
Four hundred microliters of Sample Extraction Buffer C and 650 µL of n-hexane were
added to the sample and vortexed vigorously for 1 minute. The sample was centrifuged
at 4,000 x g for 5 minutes and the upper organic layer was discarded. Ninety microliters
of the lower aqueous layer was used for the assay (dilution factor = 1.5).
Ninety microliters of each MG standard and each sample was added in duplicate
into different wells. Thirty microliters of MG-Biotin Conjugate was added and the plate
was incubated for 30 minutes at room temperature in the dark. The plate was washed 3
times with 250 µL of Wash Solution. One hundred microliters of TMB substrate was
added and the plate was incubated for 15 minutes at room temperature. After
incubation, 100 µL of Stop Buffer was added to stop the enzyme reaction and the plate
was read immediately at 450 nm wavelength.
2.2.4 Nitrofurans
One gram of the homogenized sample was weighed into 15 mL centrifuge tubes.
0.5 mL of Sample Extraction Buffer, 3.5 mL of distilled water, 0.5 mL of 1 M hydrochloric
acid (HCl), and 20 µL of 50 mM 2-Nitrobenzaldehyde were added and vortexed for 30
seconds at maximum speed. The sample were incubated for 3 hours at 50°C and
vortexed for 5 seconds every hour during the incubation. Five milliliters of 0.1 M
dipotassium phosphate (K2HPO4), 0.4 mL of sodium hydroxide (NaOH), and 6 mL of
ethyl acetate were added and vortexed for 30 seconds. The sample was centrifuged at
4,000 x g for 10 minutes at room temperature and 3.0 mL of the ethyl acetate
supernatant (corresponding to 0.5 g of the original sample) was transferred into a new
15 mL centrifuge tube. A centrifugal solvent evaporator was used to dry the sample at
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60°C under reduced pressure. The dried residue was dissolved in 1 mL of n-hexane
and 1 mL of Sample Extraction Buffer was added and vortexed for 2 minutes. The
sample was centrifuged at 4,000 x g for 10 minutes at room temperature and 100 µL of
the lower aqueous layer was used per well for the assay (dilution factor = 2).
One hundred microliters of each AMOZ standard and each sample was added in
duplicate into different wells. Fifty microliters of AMOZ-HRP Conjugate was added and
the plate was incubated for 30 minutes at room temperature. The plate was washed 3
times with 250 µL of Wash Solution. One hundred microliters of TMB substrate was
added and the plate was incubated for 20 minutes at room temperature. After
incubation, 100 µL of Stop Buffer was added to stop the enzyme reaction and the plate
was read immediately at 450 nm wavelength.
2.3 Liquid Chromatographic–Mass Spectrometric Confirmation of Residues
Quantitation of chloramphenicol and fluoroquinolone residues was accomplished
using a modification of AOAC Official Method 995.09 44. Malachite green was quantified
using a modified method for the quantitative determination of triphenylmethane dyes in
aquaculture products 45. Standards, internal standards, and all other chemicals were of
analytical or HPLC grade and purchased from Sigma Aldrich Co. (St. Louis, MO).
2.3.1 Chloramphenicol and Enrofloxacin Quantitation
Chloramphenicol and enrofloxacin were extracted from tissue with pH 4 buffer.
Filtered extract was cleaned up on C18 solid-phase extraction column. Compounds
were separated by liquid chromatography using a C8 column and measured using a
triple quadrupole mass spectrometer. Results were corrected for recovery of each
analyte for each analytical run.
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Five grams ± 0.05 g of shrimp tissue homogenate was weighed into 50 mL
polypropylene centrifuge tubes and fortified with 0.5 µg/mL analyte. Twenty milliliters
McIlvaine buffer-EDTA solution was added to each sample and blended for 30 seconds
with a homogenizer, rinsing the probe twice with 2 mL McIlvaine buffer-EDTA solution
into each tube. Tubes were shaken for 10 minutes using a flat-bed shaker at high speed
then centrifuged for 10 minutes at 2500 x g. The supernatant was transferred to a new
centrifuge tube and the extraction was repeated twice using 10 mL McIlvaine bufferEDTA solution. The combined supernatants were centrifuged for 20 minutes at 2500 x
g. The extract was filtered through glass microfiber filter paper, grade GF/B, 5.5 cm
using a Büchner funnel into 125 mL sidearm flask by applying gentle vacuum to
sidearm. The centrifuge tube was rinsed twice with 2 mL McIlvaine buffer-EDTA solution
and filtered into the sidearm flask. SPE cartridges (6 mL, 500 mg C18) were conditioned
with 20 mL methanol followed by 20 mL H2O. The extract was applied to SPE cartridge
with 75 mL reservoir attached; the sidearm flask was rinsed twice with 2 mL McIlvaine
buffer-EDTA and washings were added to the reservoir. When test extract was loaded,
the SPE cartridge was washed using 20 mL H2O from rinsing the sidearm flask. The
cartridge was allowed to run dry following H2O wash and air was drawn through for at
least 2 more minutes. Compounds were eluted from the cartridge into 10 mL volumetric
flasks using 6 mL methanolic oxalic acid. Vacuum was increased to maximum at the
end of elution to remove residual solvent from the cartridge. Eluate was diluted to 10 mL
with H2O. The test solution was filtered through 13 mm, 0.45 µm filtration cartridges into
LC vials for analysis.
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Chloramphenicol and enrofloxacin concentrations were determined using a
Waters Acquity ultra performance liquid chromatography (UPLC) system (Milford, MA)
coupled to a XEVO triple quadrupole mass spectrometer. The columns used were a
Phenomenex Kinetex C-18 column (Torrance, CA) with 2.6 µm particle size and
dimensions of 2.1 millimeter (mm) X 50 mm and a Phenomenex C18 guard column (2.1
mm X 5 mm, µm particle size). The mobile phase consisted of water with 0.1% formic
acid (mobile phase A for enrofloxacin, positive ion mode), water with 0.1% acetic acid
(mobile phase A for chloramphenicol, negative ion mode), and methanol (mobile phase
B). The initial percentage of A was 88%, which was reduced to 40% at 5 minutes, and
ramped back up to 88% at 6.5 minutes, with 0.7 mL/min constant flow rate.
2.3.2 Malachite Green Quantitation
Leucomalachite green was isolated from the matrix by liquid-liquid extraction with
acetonitrile. Determination was performed using LC-MS/MS with positive electrospray
ionization. Deuterated internal standards were used to improve quantitation. The
method has been validated according to the EU criteria of Commission Decision
2002/657/EC in accordance with the minimum required performance limit (MRPL) set at
2 µg/kg-1 for the sum of MG and LMG.
Shrimp tissue homogenate was fortified with 2 µg/mL internal standard (D5leucomalachite green). Five hundred microliters of hydroxylamine solution was added,
the sample was mixed, then allowed to stand for 10 minutes in the dark. Eight milliliters
of acetonitrile and 1 g (±0.1 g) of anhydrous magnesium sulfate were added and the
tube was vortexed vigorously for 1 minute at maximum speed, then shaken for 10
minutes with a rotative stirrer at 100 x g. The tube was centrifuged at 2000 x g for 5
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minutes at 4 °C. The supernatant was transferred to a new clean tube and evaporated
to dryness at 50 °C under nitrogen. The dried residue was reconstituted in 800 µL of
acetonitrile/ascorbic acid (100/1; v/v). The extract was transferred to an Eppendorf tube
and centrifuged at 20,000 x g for 5 minutes then filtered through a 0.45 µm PVDF filter
into an LC vial prior to LC-MS/MS analysis.
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CHAPTER 3: RESULTS AND DISCUSSION
3.1 Detection and Confirmation of Drug Residues
ELISA kits were used to rapidly screen shrimp samples to determine which drug
residues were present. Chloramphenicol, fluoroquinolones, malachite green, and
nitrofurans were the drugs chosen for screening because of their ability to cause severe
adverse effects in humans and their high enforcement priority status. The four
veterinary drugs analyzed, the detection limits for all methods, and current FDA
detection levels in parts per billion are listed in Table 3.1. ELISA (Enzyme Linked
Immnosorbent Assay) has become a favorable option for portable and high throughput
screening for drug residues in animal products because of its advantages over
conventional methods, which can be extremely expensive and time-consuming.
Commercial ELISA kits are simple, rapid, sensitive, cost-effective, and have shorter
processing times. These advantages enable government agencies, seafood processors,
and quality assurance organizations to detect drug residues in fish and shrimp matrices
at the required sensitivities without complicated clean up steps.
Table 3.1. Veterinary drugs analyzed, detection limits of methods used (ppb), and
current FDA detection levels (ppb)
Analyte

Detection Limit
Current FDA
Detection Levels
ELISA
LC-MS/MS
Chloramphenicol
0.025
0.3
0.3
Fluoroquinolones
0.2
1
5
Malachite green
0.1
0.4
1
Nitrofurans
0.05
NT
1
LC-MS/MS = liquid chromatography coupled with tandem mass spectrometry detection;
NT = not tested
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Rapid assay kits from Bioo Scientific Corporation (Austin, Texas) were used to
determine if drug residues were present in shrimp samples. The methods are based on
competitive colorimetric ELISA assays. The drug antibody has been coated in the plate
wells. During the analysis, sample is added along with an enzyme-conjugated antibody,
tagged with a peroxidase enzyme, that targets the drug antibody coated on the plate
wells. If the target is present in the sample, it will compete for the drug antibody, thereby
preventing the enzyme-conjugated antibody from binding. The resulting color intensity,
after addition of substrate, has an inverse relationship with the target concentration in
the sample.
Of the 27 samples analyzed in this study, 25 were found to contain detectable
levels of veterinary drug residues and 20 contained more than one detectable residue.
Two of the four analytes monitored in this study were detected using ELISA.
Fluoroquinolones and malachite green were detected and the results are presented in
Table 3.2. Nitrofurans were not detected in any of the samples tested. The most
frequently observed residue was malachite green, followed by fluoroquinolones. To
confirm ELISA results, samples that tested positive for both of the drugs using ELISA
(fluoroquinolones and malachite green) were sent to an external laboratory for analysis.
Although no samples were positive for chloramphenicol, it was also analyzed using
confirmatory testing because of its severe adverse health effects, notably its ability to
cause fatal aplastic anemia, and because even the spiked samples analyzed using
ELISA were negative, suggesting that the extraction procedure was unsuccessful.
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Table 3.2. Concentration of veterinary drugs (ppb) in shrimp as detected by ELISA
Fluoroquinolone
Concentration
Thailand
ND
ND
ND
1.312 ± 0.05
ND
1.798 ± 0.07
1.262 ± 0.07
1.735 ± 0.11
1.979 ± 0.10
1.316 ± 0.01
ND
4.174 ± 0.09
1.647 ± 0.10
2.361 ± 0.03
1.701 ± 0.12
Indonesia
1.468 ± 0.09
1.636 ± 0.07
1.442 ± 0.06
ND
ND
India
2.220 ± 0.02
1.536 ± 0.00
Vietnam
1.792 ± 0.03
China
1.594 ± 0.07
Ecuador
2.174 ± 0.01
Vietnam-Thailand
2.837 ± 0.11
India-Indonesia
1.378 ± 0.08
United States
ND
Values are expressed as mean±SD
Country of Origin

Malachite Green
Concentration
2.776 ± 0.00
1.432 ± 0.02
1.438 ± 0.03
1.311 ± 0.00
3.031 ± 0.02
3.757 ± 0.00
1.567 ± 0.02
1.306 ± 0.01
1.800 ± 0.01
0.936 ± 0.01
3.151 ± 0.02
1.883 ± 0.02
1.144 ± 0.04
1.910 ± 0.00
1.986 ± 0.01
2.077 ± 0.03
0.723 ± 0.04
0.676 ± 0.02
ND
ND
1.037 ± 0.03
0.354 ± 0.63
2.181 ± 0.01
1.902 ± 0.00
1.041 ± 0.02
1.111 ± 0.03
1.151 ± 0.02
ND

3.2.1 Chloramphenicol
The detection limit for the chloramphenicol ELISA was 0.025 ppb in fish and
shrimp. The antibody is 100% cross-reactive with chloramphenicol and exhibits 76.8%
cross-reactivity with the main metabolite chloramphenicol glucuronide (Table 3.3). No
samples tested positive for chloramphenicol residues. The average variability in
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absorbance between duplicate samples was 4.5%, where 25% was considered
acceptable. This was determined as follows:
2(𝑥 − 𝑦)
∗ 100
𝑥+𝑦
Table 3.3: Cross-reactivity profile for chloramphenicol ELISA
Analytes

Cross-reactivity (%)

Chloramphenicol

100

Chloramphenicol Glucuronide

100

Chloramphenicol base

90

Thiamphenicol

45

Tetracyclines

36

Gentamicin

31

Ampicillin

21

Florfenicol

10

Using LC-MS/MS, chloramphenicol residues were detected in three of the five
samples that were tested. The concentrations ranged from 0.30 to 0.49 ppb. Samples 1,
2, and 4 had detectable levels of chloramphenicol, despite the negative ELISA results
for those samples. The multiple reaction monitoring (MRM) extracted ion chromatogram
(XIC) for chloramphenicol in samples 1, 2, and 4 are presented in figures 3.1, 3.2, and
3.3, respectively. Published reports have demonstrated that fish and shrimp purchased
at the retail level may contain veterinary drug residues that are banned for use in foodproducing animals in the United States 46. An analysis of veterinary drug residues in fish
in shrimp samples collected in Canada between 1993 and 2004 resulted in the
detection of drug residues in nine of the 30 samples analyzed, with four containing more
than one detectable residue 46. A survey of animal products in China detected
chloramphenicol residues in 23 out of 28 aquacultured fish samples in 2013 47.
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Figure 3.1: Extracted ion chromatogram for chloramphenicol in sample 1
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Figure 3.2: Extracted ion chromatogram for chloramphenicol in sample 2
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Figure 3.3: Extracted ion chromatogram for chloramphenicol in sample 4
3.2.2 Fluoroquinolones
The fluoroquinolone ELISA had a detection limit of 0.2 ppb in fish and shrimp and
is 100% cross-reactive with both enrofloxacin and its primary metabolite ciprofloxacin.
The antibody also displays substantial cross-reactivity with several other antimicrobial
drugs (Table 3.4). Twenty samples tested positive for fluoroquinolone residues, with
concentrations ranging from 1.31 to 4.17 ppb. The average variability in absorbance
between duplicate samples was 5.03%.
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Table 3.4: Cross-reactivity profile for fluoroquinolone ELISA
Analytes

Cross-reactivity (%)

Enrofloxacin

100

Ciprofloxain

100

Danofloxacin

90

Norfloxacin

45

Enofloxacin

36

Pipemidic acid

31

Ofloxacin

21

Benofloxacin

10

Flumequin

8

Oxolin acid

7

Using LC-MS/MS, enrofloxacin residues were confirmed in two of the five
samples that were positive using ELISA. Mass spectrometric analysis of samples 2 and
3 detected 5.95 and 1.22 ppb enrofloxacin, respectively. The confirmed concentration
for sample 2 was higher than the concentration detected in that sample using ELISA,
and the confirmed concentration for sample 3 was lower than the ELISA concentration
for that sample. The multiple reaction monitoring (MRM) extracted ion chromatogram
(XIC) for enrofloxacin in samples 2 and 3 are presented in figures 3.4 and 3.5,
respectively. In a study published in 2007, the fluoroquinolone enrofloxacin was
detected in three out of 30 samples of farm-raised seafood in the United Kingdom in
1994 to 1995 46.
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Figure 3.4: Extracted ion chromatogram for enrofloxacin in sample 2
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Figure 3.5: Extracted ion chromatogram for enrofloxacin in sample 3
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3.2.3 Malachite Green
The detection limit for the malachite green ELISA was 0.1 ppb in shrimp. The
antibody exhibits cross-reactivity of 100% with both malachite green and its primary
metabolite, leucomalachite green. The antibody is also considerably cross-reactive with
crystal violet, another triphenylmethane dye that is commonly used in aquaculture, at
42% (Table 3.5). Twenty-five samples tested positive for malachite green residues, with
concentrations ranging from 0.35 to 3.76 ppb. The average variability in absorbance
between duplicate samples was 14.6%. Five positive ELISA samples were analyzed for
leucomalachite green using LC-MS/MS, and residues were not confirmed in any of the
five samples.
Table 3.5: Cross-reactivity profile for malachite green ELISA
Analytes

Cross-reactivity (%)

Malachite Green

100

Leucomalachite Green

100

Crystal Violet

42

Leucocrystal Violet

<0.01

Diethylstilbestrol

<0.01

Sulfumethazine

<0.01

Chloramphenicol

<0.01

Furazolidone

<0.01

A study published in 2003 reported the malachite green metabolite
leucomalachite green was detected in 13 out of 18 trout samples purchased from
markets in the Netherlands at concentrations ranging from 1.3 to 14.9 ng g-1 48.
Leucomalachite green was also detected in eight out of 12 trout samples purchased
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from markets in the United Kingdom in 1994 to 1995 at concentrations ranging from
<0.5 to 96 ng g-1 49
3.2.4 Nitrofurans
The detection limit for the nitrofuran ELISA was 0.05 ppb for fish and shrimp. The
antibody exhibits 100% cross-reactivity with the primary metabolite of furaltadone,
3-amino-5-methylmorpholino-2-oxazolidinone (AMOZ) and negligible cross-reactivity
with other compounds. No samples tested positive for nitrofuran residues. The average
variability in absorbance between duplicate samples was 2.27%. Although no nitrofuran
residues were detected in this study, their presence in shrimp has been documented in
literature. Nitrofuran metabolites were detected in Thai-originating shrimp sampled been
2000 and 2003 in the European Union 46,50. A Swiss study published in 2003 detected
nitrofuran residues in shrimp from Asian countries in 54 out of 157 samples at 0.2–150
ng g-1 51.
The results from the ELISA screening and LC-MS/MS confirmation of drug
residues in imported shrimp samples are presented in Table 3.6. Four of the five shrimp
samples analyzed using mass spectrometry were found to contain detectable levels of
veterinary drug residues, with one sample containing multiple residues.
Chloramphenicol and fluoroquinolones were detected using confirmatory methods. The
most frequently observed residue by LC-MS/MS detection was chloramphenicol,
followed by fluoroquinolones. Malachite green was not present in any of the five
samples, although it was detected using ELISA.
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Table 3.6. Concentration of veterinary drugs (ppb) in shrimp as detected by ELISA
and confirmed using LC-MS/MS
Sample
Analyte
1
Chloramphenicol
Enrofloxacin
Leucomalachite green

ELISA Confirmation
ND
0.43
1.47
ND
2.08
ND

2

Chloramphenicol
Enrofloxacin
Leucomalachite green

ND
1.64
0.72

0.49
5.95
ND

3

Chloramphenicol
Enrofloxacin
Leucomalachite green

ND
2.22
1.04

ND
1.22
ND

4

Chloramphenicol
Enrofloxacin
Leucomalachite green

ND
1.79
2.18

0.30
ND
ND

5

Chloramphenicol
Enrofloxacin
Leucomalachite green

ND
1.59
1.90

ND
ND
ND

ND = none detected
The correlation between residue concentrations from ELISA screening and
confirmatory testing is generally poor 52; however, drug residue kits can be useful for
qualitative screening of the compounds in shrimp tissue. The discrepancies between
detected concentrations in ELISA and confirmatory methods are thought to be due to
cross-reactivity with other compounds, matrix effects, differences in detection limits of
the two methods, or contamination of ELISA samples.
Biological matrices are extremely complex, making the analysis of biological
samples challenging. High levels of interfering factors can lead to unexpected ELISA
results. Analysis is often hampered by the presence of endogenous compounds in the
sample; the interferences are often present in higher concentrations than that of the
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target analytes and thus may mask their presence. Sample preparation is an important
aspect of bioanalytical estimation because biological samples are comprised of many
components that can interfere with good separations and or good mass spectrometer
signals.
In addition to matrix effects, the presence of interfering compounds from the
same group as the analyte can affect the correlation between ELISA and
chromatographic results. Enrofloxacin, the main target drug of the fluoroquinolone
ELISA, was chosen for confirmatory testing. The fluoroquinolone ELISA was highly
cross-reactive with several fluoroquinolones that are commonly used in aquaculture but
were not analyzed chromatographically, thereby possibly contributing to the failure to
detect enrofloxacin using LC-MS/MS. The malachite green ELISA was cross-reactive
with gentian violet, another triphenylmethane dye that is toxic to humans and frequently
used in aquaculture, but gentian violet was not analyzed chromatographically.
Contamination of ELISA samples was a possibility owing to the sensitivity of
immunoassays. The failure to detect chloramphenicol using ELISA, even in spiked
samples and despite having a good standard curve, suggests the extraction procedure
or extraction buffers may have been inadequate. The results of this study emphasize
why ELISA results have to be confirmed quantitatively.
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CHAPTER 4. SUMMARY AND CONCLUSIONS
The objective of this research was to quantify veterinary drug residues in
imported, farm-raised shrimp and make this information available to the general public
in order evaluate the effectiveness of current imported seafood testing, thus contributing
to the collective data on the topic. The use of unapproved veterinary drugs to treat
shrimp in aquaculture systems results in the accumulation of drug residues in the edible
tissues of the shrimp. These illegal drug residues can negatively impact human health,
making routine testing imperative in order to protect consumers.
The results of this study confirm the presence of illegal veterinary drug residues
in shrimp sold at the retail level in the United States. Ninety-two percent of imported,
farm-raised shrimp samples tested positive for at least one drug that is banned for use
in food-producing animals in the United States. Two of the four drugs considered in this
study were detected using ELISA: fluoroquinolones and malachite green. The
fluoroquinolone enrofloxacin was confirmed in two out of five samples using LC-MS/MS.
Malachite green could not be detected using confirmatory methods. Chloramphenicol
was not detected using ELISA, but was detected in three out of five samples using LCMS/MS.
The residue concentrations detected in this study are within the ranges described
in the few published reports regarding veterinary drug residues in fish and shrimp
purchased at the retail level. Considering the above, ELISA can be a useful tool for the
qualitative screening of shrimp muscle tissue for drug residues, but the results of this
study suggest that more evaluation of commercial kits is necessary. Further testing is
needed to investigate the safety of other imported, farm-raised aquaculture species and
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to determine the extent of imported seafood contamination. Wild-caught shrimp from the
United States tested negative for all veterinary drugs considered.	
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